AIM: To assess the efficacy and safety of ranitidine bismuth citrate plus clarithromycin given for 1 wk in Brazilian patients with peptic ulcer. METHODS:One hundred and twenty patients with peptic ulcer were randomized in two treatment groups: (1) 1-wk regimen consisting of ranitidine bismuth citrate 400 mg b.i.d. with clarithromycin 500 mg b.i.d. or (2) 2-wk regimen of the same treatment. Eradication of the infection was considered when both the histologic examination and the urease test were negative for the infection 3 mo after treatment. RESULTS: By intention to treat analysis, Helicobacter pylori (H pylori) was eradicated in 73% and 76% of patients, respectively treated for 1 or 2 wk (P>0.05). By per protocol analysis, the eradication rates were 80% and 83%, respectively, in patients treated for 1 or 2 wk (P>0.05). Nine patients (8.2%) reported minor side effects. CONCLUSION: One-week therapy with ranitidine bismuth citrate and clarithromycin is safe, well tolerated and effective for treatment of H pylori infection, and appears to be comparable to the 2-wk regimen in terms of efficacy.
RCT Entities:
AIM: To assess the efficacy and safety of ranitidine bismuth citrate plus clarithromycin given for 1 wk in Brazilian patients with peptic ulcer. METHODS: One hundred and twenty patients with peptic ulcer were randomized in two treatment groups: (1) 1-wk regimen consisting of ranitidine bismuth citrate 400 mg b.i.d. with clarithromycin 500 mg b.i.d. or (2) 2-wk regimen of the same treatment. Eradication of the infection was considered when both the histologic examination and the urease test were negative for the infection 3 mo after treatment. RESULTS: By intention to treat analysis, Helicobacter pylori (H pylori) was eradicated in 73% and 76% of patients, respectively treated for 1 or 2 wk (P>0.05). By per protocol analysis, the eradication rates were 80% and 83%, respectively, in patients treated for 1 or 2 wk (P>0.05). Nine patients (8.2%) reported minor side effects. CONCLUSION: One-week therapy with ranitidine bismuth citrate and clarithromycin is safe, well tolerated and effective for treatment of H pylori infection, and appears to be comparable to the 2-wk regimen in terms of efficacy.
Authors: P Malfertheiner; F Mégraud; C O'Morain; D Bell; G Bianchi Porro; M Deltenre; D Forman; G Gasbarrini; B Jaup; J J Misiewicz; J Pajares; M Quina; E Rauws Journal: Eur J Gastroenterol Hepatol Date: 1997-01 Impact factor: 2.566
Authors: C Ecclissato; M A M Marchioretto; S Mendonça; A P O Godoy; R A Guersoni; M Deguer; H Piovesan; J G P Ferraz; J Pedrazzoli Journal: Helicobacter Date: 2002-02 Impact factor: 5.753
Authors: K D Bardhan; D Morton; M J Perry; D S Sanders; P Morris; A Rowland; M Thompson; T R Mitchell; P M Roberts Journal: Aliment Pharmacol Ther Date: 2001-08 Impact factor: 8.171
Authors: H Hamada; K Haruma; M Mihara; T Kamada; M Yoshihara; K Sumii; G Kajiyama; M Kawanishi Journal: Aliment Pharmacol Ther Date: 2000-06 Impact factor: 8.171
Authors: S Mendonça; C Ecclissato; M S Sartori; A P Godoy; R A Guerzoni; M Degger; J Pedrazzoli Journal: Helicobacter Date: 2000-06 Impact factor: 5.753
Authors: P Pozzato; M Zagari; A Cardelli; F A Catalano; A Giglio; F Lami; A Pilotto; G Scarpulla; A Spadaccini; D Susi; R Tosatto; A Olivieri; F Bazzoli; E Roda Journal: Aliment Pharmacol Ther Date: 1998-05 Impact factor: 8.171